Long-term disease-free survival after nonmyeloablative cyclophosphamide/ fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1300-1308

  Nelson, R P ^a   Yu, M ^a   Schwartz, J E ^a   Robertson, M J ^a   Hromas, R ^b   Fausel, C A ^a   Vance, G H ^a   Dlouhy, S R ^a   Baute, J A ^a   Cox, E A ^a   Wood, L L ^a   Srivastava, S ^a   Robertson, K A ^a   Haut, P R ^a   Farag, S S ^a   Abonour, R ^a   Cornetta, K ^a   Cripe, L D ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

leukemia; minimal intensity; myelodysplasia; nonmyeloablative; transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CD3+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 77955575938     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.348     Document Type: Article

References (73)

1. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
2. Chopra R, Goldstone AH. Modern trends in bone marrow transplantation for acute myeloid and acute lymphoblastic leukemia. Curr Opin Oncol 1992; 4: 247-258.
3. Morgenstern GR, Powles RL. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. Haematol Blood Transfus 1981; 26: 139-142.
4. Speck B. [Indications for bone marrow transplantation in aplastic anemia and acute myeloid leukemia]. Schweiz Med Wochenschr 1973; 103: 508-511.
5. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allo- geneic marrow transplantation. Blood 1977; 49: 511-533.
6. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
7. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus- malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
8. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
9. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
10. Grigg A, Bardy P, Byron K, Seymour JF, Szer J. Fludarabine- based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107-110.
11. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyelo- ablative transplants: preclinical and clinical results. Semin Oncol 2000; 27: 78-81.
12. Storb R, Yu C, Sandmaier B, McSweeney P, Georges G, Nash R et al. Mixed hematopoietic chimerism after hema- topoietic stem cell allografts. Transplant Proc 1999; 31: 677-678.
13. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
14. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
15. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
16. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128-135.
17. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-328.
18. Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol 2007; 19: 660-666.
19. Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455-460.
20. Ringden O, Kersey JH. Prevention and therapy of graft- versus-host disease. Report from a work-shop. Bone Marrow Transplant 1992; 10(Suppl 1): 22-24.
21. Flowers ME, Traina F, Storer B, Maris M, Bethge WA, Carpenter P et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant 2005; 35: 277-282. (Pubitemid 40268300)
22. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
23. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20: 1673-1682.
24. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
25. Sykes M, Eisenthal A, Sachs DH. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 1988; 140: 2903-2911.
26. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191-195.
27. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006; 13: 26-41.
28. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Huntingt) 2003; 17: 94-100; discussion 103-107
29. Hurley CK, Baxter Lowe LA, Logan B, Karanes C, Anasetti C, Weisdorf D et al. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003; 9: 610-615.
30. 34+ cells from normal donors. Bone Marrow Transplant 2000; 26: 1271-1279.
31. Boeckh M, Myerson D, Bowden RA. Early detection and treatment of cytomegalovirus infections in marrow transplant patients: methodological aspects and implications for therapeutic interventions. Bone Marrow Transplant 1994; 14(Suppl 4): S66-S70.
32. Puregene Genomic DNA Isolation Kit Instructions Gentra Systems, 13355 10th Ave North, Suite 120, Minneapolis MN.
33. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M et al. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987; 235: 1616-1622.
34. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4(Suppl 1): 42-93.
35. Socie G. Chronic graft-versus-host disease: clinical features and grading systems. Int J Hematol 2004; 79: 216-220.
36. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
37. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
38. Dulley FL, Shulman HM, Massumoto CM, Loterio HA, Dorlhiac-Llacer PE, Beitler B et al. Late onset of acute graft-versus-host disease. Clin Transpl 1989; 312.
39. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570.
40. Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484-493.
41. Cavalier M, Shmalo JA, Yu M, Billings SD, Abonour R, Nelson Jr RP. Skin cancer after nonmyeloablative hemato- poietic cell transplantation. Bone Marrow Transplant 2006; 37: 1103-1108.
42. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclo- phosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007; 13: 560-567.
43. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
44. Pandurangadu AV, Yu M, Nelson Jr RP. Early expansion of lymphoid cells precedes myeloid engraftment following hematopoietic cell transplantation using truly nonmyeloabla- tive cyclophosphamide/fludarabine conditioning. Biol Blood Marrow Transpl 2007; 13: 96 (abstract).
45. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematolo- gical malignancies. Drugs 1997; 53: 1005-1037.
46. Beelen DW, Quabeck K, Mahmoud HK, Sayer HG, Kraft J, Graeven U et al. [Maintenance of remission in acute myeloid leukemia by allogeneic or autologous bone marrow transplantation]. Dtsch Med Wochenschr 1991; 116: 401-410.
47. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
48. Aschan J, Ringden O. Prognostic factors for long- term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Clin Transplant 1994; 8: 258-270.
49. Fagioli F, Bacigalupo A, Frassoni F, Van Lint MT, Occhini D, Gualandi F et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplant 1994; 13: 247-252.
50. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allo- geneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951-956.
51. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
52. Jourdan E, Maraninchi D, Reiffers J, Gluckman E, Rio B, Jouet JP et al. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 1997; 19: 875-881.
53. Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002; 8: 435-443.
54. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ. The graft-versus-leukemia effect of nonmyelo- ablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897-901.
55. Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 749-757.
56. Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after HLA- identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008; 41: 33-38.
57. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130: 256-264.
58. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
59. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454-462. (Pubitemid 46421890)
60. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced- intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelo- dysplasia. J Clin Oncol 2005; 23: 9387-9393.
61. Slavin S, Strober S, Fuks Z, Kaplan HS. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science 1976; 193: 1252-1254.
62. Sykes M, Chester CH, Sachs DH. Protection from graft- versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow. Transplantation 1988; 46: 327-330.
63. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966; 62: 21-78.
64. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
65. Jadus MR, Wepsic HT. The role of cytokines in graft-versus- host reactions and disease. Bone Marrow Transplant 1992; 10: 1-14.
66. Krenger W, Ferrara JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996; 5: 3-14.
67. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM et al. Inflammatory cytokines and acute graft- versus-host disease after reduced-intensity conditioning allo- geneic stem cell transplantation. Blood 2005; 106: 4407-4411.
68. Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev 2008; 19: 53-63.
69. Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 527-530. (Pubitemid 39264044)
70. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-486.
71. Waldmann H. Therapeutic approaches for transplantation. Curr Opin Immunol 2001; 13: 606-610.
72. Ji SQ, Chen HR, Yan HM, Wang HX, Liu J, Zhu PY et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005; 36: 349-354.
73. Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A et al. Pharmacokinetics of intravenous myco- phenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176-184. (Pubitemid 32496142)